In Good Company with Nicolai Tangen
HIGHLIGHTS: Emma Walmsley - CEO of GSK
Apr 4, 2025
Emma Walmsley, CEO of GSK and a leader in the pharmaceutical sector, shares fascinating insights on drug discovery and company culture. She discusses GSK's innovative advancements in cancer treatments and HIV therapies. Emma highlights the transformative role of AI in speeding up drug development. She emphasizes the importance of balancing drug accessibility and pricing, alongside the necessity of curiosity and partnership in navigating change. Tune in for her vision on reshaping healthcare for billions around the globe!
10:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GSK is advancing pharmaceutical innovation through new drug formulations and AI technology, aiming to tackle global health challenges effectively.
- The conversation highlights the critical need for public education and transparency in addressing vaccine hesitancy, ensuring community trust in public health initiatives.
Deep dives
Innovative Drug Development
The conversation emphasizes the excitement surrounding the development of new drugs and vaccines that aim to address significant health challenges globally. This year, there are five anticipated approvals for new therapies, with a pipeline of 14 key medicines and vaccines expected to launch within the decade. Notably, advancements in treatment for multiple myeloma through antibody drug conjugates showcase the potential for more effective cancer therapies with fewer side effects. Additionally, breakthroughs in gene-targeting technology like oligonucleotides could lead to functional cures for widespread diseases such as hepatitis B, pointing to a promising future in pharmaceutical innovation.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
